Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.65 |
| ▸ | KDR | P35968 | 8/20 | 0.56 |
| ▸ | TEK | Q02763 | 7/20 | 0.56 |
| ▸ | MMP1 | P03956 | 1/20 | 0.54 |
| ▸ | RAF1 | P04049 | 1/20 | 0.49 |
| ▸ | BRAF | P15056 | 1/20 | 0.49 |
| ▸ | MTOR | P42345 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11359812 | 0.90 | LMNA (0.77) | LMNACYP1A2MEN1NR1I2KMT2A | |
| SCHEMBL6029536 | 0.85 | LMNA (0.77) | LMNACYP1A2MEN1NR1I2KMT2A | |
| SCHEMBL7012558 | 0.82 | KDR (0.55) | LMNACYP1A2MEN1NR1I2KMT2A | |
| SCHEMBL6235584 | 0.80 | LMNA (0.62) | LMNACYP1A2MEN1NR1I2KMT2A | |
| SCHEMBL14375461 | 0.80 | KDR (0.76) | LMNACYP1A2MEN1NR1I2KMT2A | |
| SCHEMBL928813 | 0.80 | KMT2A (0.52) | LMNACYP1A2MEN1NR1I2KMT2A | |
| SCHEMBL7018064 | 0.80 | CDK8 (0.56) | MEN1KMT2AMAPK14KDRTEK | |
| SCHEMBL14375458 | 0.80 | KDR (0.75) | LMNACYP1A2MEN1NR1I2KMT2A | |
| Fenbendazole SCHEMBL8469702 | 0.79 | LMNA (1.00) | LMNACYP1A2MEN1NR1I2KMT2A | |
| Fenbendazole SCHEMBL30384658 | 0.79 | LMNA (1.00) | LMNACYP1A2MEN1NR1I2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060264492-A1 | Benzimidazole vascular damaging agents | ANGIOGENE PHARMACEUTICALS LTD. | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264492-A1 | Benzimidazole vascular damaging agents | FLT4, PCNA, FLT1 | LMNA 1373/4885CYP1A2 2222/4885MEN1 4586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.